Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with lamivudine.

Nancy Leung1

  • 1Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China. nancyleung@cuhk.edu.hk

Seminars in Liver Disease
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity.

Journal of human genetics·2020
Same author

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

Hepatology (Baltimore, Md.)·2011
Same author

Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance.

Hepatology international·2011
Same author

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.

Liver international : official journal of the International Association for the Study of the Liver·2011
Same author

Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.

Liver international : official journal of the International Association for the Study of the Liver·2011
Same author

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.

The Korean journal of hepatology·2010
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Lamivudine effectively treats chronic hepatitis B, but long-term use leads to viral resistance. This necessitates developing new, durable antiviral therapies for hepatitis B virus (HBV) infection.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B virus (HBV) infection affects millions globally.
  • Lamivudine, an oral nucleoside analogue, is a treatment option for chronic hepatitis B.
  • Current treatments face challenges with long-term efficacy and resistance.

Purpose of the Study:

  • To evaluate the efficacy and safety of lamivudine in treating chronic hepatitis B.
  • To assess the long-term outcomes and resistance patterns associated with lamivudine therapy.
  • To identify the need for novel therapeutic agents against HBV.

Main Methods:

  • Clinical trials involving HBeAg-positive and HBeAg-negative patients with chronic hepatitis B.
  • Assessment of virological, biochemical, and histological responses to lamivudine treatment.

Related Experiment Videos

  • Monitoring for the emergence of HBV resistance and treatment-related adverse events.

    • Main Results:

    • Lamivudine demonstrated rapid virological and biochemical responses in most patients.
    • Significant histological improvements were observed after 52 weeks of treatment.
    • Long-term lamivudine therapy was associated with a high incidence of HBV resistance and virological rebound.

    Conclusions:

    • While lamivudine offers short-term benefits for chronic hepatitis B, durable remission is not consistently achieved.
    • Prolonged lamivudine use frequently leads to the development of HBV resistance.
    • There is an ongoing need for safe, effective oral antiviral agents with durable activity against HBV.